Literature DB >> 15790363

The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice.

Teresa P DiLorenzo1, David V Serreze.   

Abstract

Type 1 diabetes (T1D) in both humans and nonobese diabetic (NOD) mice is a T-cell-mediated autoimmune disease in which the insulin-producing pancreatic islet beta-cells are selectively eliminated. As a result, glucose metabolism cannot be regulated unless exogenous insulin is administered. Both the CD4(+) and the CD8(+) T-cell subsets are required for T1D development. Approximately 20 years ago, an association between certain class II major histocompatibility complex (MHC) alleles and susceptibility to T1D was reported. This finding led to enormous interest in the CD4(+) T cells participating in the development of T1D, while the CD8(+) subset was relatively ignored. However, the isolation of beta-cell-autoreactive CD8(+) T-cell clones from the islets of NOD mice helped to generate interest in the pathogenic role of this subset, as has accumulating evidence that certain class I MHC alleles are additional risk factors for T1D development in humans. Three distinct diabetogenic CD8(+) T-cell populations have now been characterized in NOD mice. Here, we review recent investigations exploring their selection, activation, trafficking, and antigenic specificities. As CD8(+) T cells are suspected contributors to beta-cell demise in humans, continued exploration of these critical areas could very possibly lead to tangible benefits for T1D patients and at-risk individuals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790363     DOI: 10.1111/j.0105-2896.2005.00244.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  31 in total

Review 1.  Genetics, pathogenesis and clinical interventions in type 1 diabetes.

Authors:  Jeffrey A Bluestone; Kevan Herold; George Eisenbarth
Journal:  Nature       Date:  2010-04-29       Impact factor: 49.962

2.  Beyond HLA-A*0201: new HLA-transgenic nonobese diabetic mouse models of type 1 diabetes identify the insulin C-peptide as a rich source of CD8+ T cell epitopes.

Authors:  Zoltan Antal; Jason C Baker; Carla Smith; Irene Jarchum; Jeffrey Babad; Gayatri Mukherjee; Yang Yang; John Sidney; Alessandro Sette; Pere Santamaria; Teresa P DiLorenzo
Journal:  J Immunol       Date:  2012-04-25       Impact factor: 5.422

Review 3.  Role of T cells and dendritic cells in glomerular immunopathology.

Authors:  Christian Kurts; Felix Heymann; Veronika Lukacs-Kornek; Peter Boor; Jürgen Floege
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

4.  CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.

Authors:  Ekua W Brenu; Timothy J Bartley; Casey M Wright; Emma E Hamilton-Williams
Journal:  Immunol Cell Biol       Date:  2017-06-14       Impact factor: 5.126

Review 5.  Autoimmune effector memory T cells: the bad and the good.

Authors:  Priyadharshini Devarajan; Zhibin Chen
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 6.  Targeted immune interventions for type 1 diabetes: not as easy as it looks!

Authors:  Mark R Rigby; Mario R Ehlers
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-08       Impact factor: 3.243

Review 7.  Targeting the pancreatic β-cell to treat diabetes.

Authors:  Amedeo Vetere; Amit Choudhary; Sean M Burns; Bridget K Wagner
Journal:  Nat Rev Drug Discov       Date:  2014-02-14       Impact factor: 84.694

8.  Pre-existing autoimmunity determines type 1 diabetes outcome after Flt3-ligand treatment.

Authors:  Tom L Van Belle; Therese Juntti; Jeanette Liao; Matthias G von Herrath
Journal:  J Autoimmun       Date:  2009-12-09       Impact factor: 7.094

9.  Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes.

Authors:  George S Eisenbarth
Journal:  Diabetes       Date:  2010-04       Impact factor: 9.461

10.  Analysis of T cell receptor beta chains that combine with dominant conserved TRAV5D-4*04 anti-insulin B:9-23 alpha chains.

Authors:  Li Zhang; Jean M Jasinski; Masakazu Kobayashi; Bennett Davenport; Kelly Johnson; Howard Davidson; Maki Nakayama; Kathryn Haskins; George S Eisenbarth
Journal:  J Autoimmun       Date:  2009-03-16       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.